BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

To-BBB technologies BV And Lundbeck Inc. (formerly Ovation Pharmaceuticals) To Join Forces On Brain Delivery Of Antibodies For CNS Diseases


12/22/2009 10:30:24 AM

Leiden, December 22nd 2009 to-BBB, the Dutch drug brain delivery company, and the pharmaceutical company H. Lundbeck A/S are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.

“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”

Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.

Thanks to the advances of biotechnology, therapeutic antibodies have become well-established treatment modalities to address many systemic diseases. The blood-brain barrier (BBB) is unfortunately a significant obstacle in the treatment of CNS disorders, since it prevents delivery of many drug candidates to their disease target.

to-BBB's proprietary G-Technology™ is a safe technology for drug delivery to the brain and is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. The company has shown proof of concept in several model systems, including brain microdialysis, pain inhibition, viral encephalitis and brain tumors, based on which Lundbeck will now evaluate the technology in their labs.

About to-BBB

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and has established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES